國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Poor quality pharmaceuticals in glob...

Kimura, Satoru.

Poor quality pharmaceuticals in global public health

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Poor quality pharmaceuticals in global public healthby Satoru Kimura, Yasuhide Nakamura.
作者:	Kimura, Satoru.
其他作者:	Nakamura, Yasuhide.
出版者:	Singapore :Springer Singapore :2020.
面頁冊數:	xxiii, 191 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	DrugsQuality control.
電子資源:	https://doi.org/10.1007/978-981-15-2089-1
ISBN:	9789811520891$q(electronic bk.)

Poor quality pharmaceuticals in global public health
Kimura, Satoru.

Poor quality pharmaceuticals in global public health[electronic resource] /by Satoru Kimura, Yasuhide Nakamura. - Singapore :Springer Singapore :2020. - xxiii, 191 p. :ill., digital ;24 cm. - Trust, interdisciplinary perspectives,v.52509-7679 ;. - Trust, interdisciplinary perspectives ;1..

Preface -- Global aspect of imitated products and poor quality pharmaceuticals -- Problem awareness among the WHO and other major international organizations -- Precedent academic works and media reports -- Bias or misleading by the WHO? -- Standardization and its advantages in globalization -- Global events associated with modern medicines -- WHO medicines policy in public health -- IMPACT and conflicts of international society -- Case study I: Access to medicines in Indonesia -- Case study II: Supply side of medicines in India -- Case study III: Health-care service market in Japan -- An interpretation and lessons to learn.

This book aims to clarify the global aspects of poor quality pharmaceuticals, generic products in particular, becoming complicated through the process of IMPACT (International Medical Products Anti-Counterfeiting Taskforce) organized by the initiative of the World Health Organization (WHO) in 2006. The findings from this book provide a long-term perspective to policymakers. This book discusses from the following points: industrial standardization, healthcare market accessibility, motivation on supply side, WHO medicines policy and intellectual property rights. Standardization regulates the quality and enabled the generic medicines spreading to developing/emerging countries through technology transfer. However, quality is a part of cost and reflected to price. When a healthcare service market is divided according to wealth gap, compliance to standardization for quality on supply side is divided accordingly. Thus, poor quality pharmaceuticals are prevalent worldwide. Generic pharmaceuticals are essential resources in public health. The WHO has been involved in the dispute around the intellectual property rights under its intention to promote the new drug development for neglected diseases. Global pandemic of AIDs is a critical factor to accelerate the confusion. This created feelings of distrust among developing/emerging countries against developed countries if the WHO was in favour of developed countries. In addition to that, an easy and optimistic start of IMPACT stirred up conflicts of interests in the international community. The problem of poor quality pharmaceuticals became more complicated through the conflicts on intellectual property rights; patented drugs to generic drugs. A key for quality generic products is the formation of a single healthcare service market where good motivation on supply side together with fair competitiveness with patented pharmaceuticals and equitable access to services (both for the rich and the poor) are ensured. Political commitment to investment and regulatory infrastructure for the market is crucial.

ISBN: 9789811520891$q(electronic bk.)

Standard No.: 10.1007/978-981-15-2089-1doiSubjects--Topical Terms:

303164
Drugs
--Quality control.

LC Class. No.: RM301 / .K568 2020

Dewey Class. No.: 615.1

Poor quality pharmaceuticals in global public health
LDR:03755nmm a2200337 a 4500 001 573832
003 DE-He213
005 20200706143835.0
006 m d
007 cr nn 008maaau
008 200928s2020 si s 0 eng d
020 $a 9789811520891$q(electronic bk.)
020 $a 9789811520884$q(paper)
024 7 $a 10.1007/978-981-15-2089-1 $2 doi
035 $a 978-981-15-2089-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301 $b .K568 2020
072 7 $a MBN $2 bicssc
072 7 $a MED078000 $2 bisacsh
072 7 $a MBN $2 thema
082 0 4 $a 615.1 $2 23
090 $a RM301 $b .K49 2020
100 1 $a Kimura, Satoru. $3 861275
245 1 0 $a Poor quality pharmaceuticals in global public health $h [electronic resource] / $c by Satoru Kimura, Yasuhide Nakamura.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2020.
300 $a xxiii, 191 p. : $b ill., digital ; $c 24 cm.
490 1 $a Trust, interdisciplinary perspectives, $x 2509-7679 ; $v v.5
505 0 $a Preface -- Global aspect of imitated products and poor quality pharmaceuticals -- Problem awareness among the WHO and other major international organizations -- Precedent academic works and media reports -- Bias or misleading by the WHO? -- Standardization and its advantages in globalization -- Global events associated with modern medicines -- WHO medicines policy in public health -- IMPACT and conflicts of international society -- Case study I: Access to medicines in Indonesia -- Case study II: Supply side of medicines in India -- Case study III: Health-care service market in Japan -- An interpretation and lessons to learn.
520 $a This book aims to clarify the global aspects of poor quality pharmaceuticals, generic products in particular, becoming complicated through the process of IMPACT (International Medical Products Anti-Counterfeiting Taskforce) organized by the initiative of the World Health Organization (WHO) in 2006. The findings from this book provide a long-term perspective to policymakers. This book discusses from the following points: industrial standardization, healthcare market accessibility, motivation on supply side, WHO medicines policy and intellectual property rights. Standardization regulates the quality and enabled the generic medicines spreading to developing/emerging countries through technology transfer. However, quality is a part of cost and reflected to price. When a healthcare service market is divided according to wealth gap, compliance to standardization for quality on supply side is divided accordingly. Thus, poor quality pharmaceuticals are prevalent worldwide. Generic pharmaceuticals are essential resources in public health. The WHO has been involved in the dispute around the intellectual property rights under its intention to promote the new drug development for neglected diseases. Global pandemic of AIDs is a critical factor to accelerate the confusion. This created feelings of distrust among developing/emerging countries against developed countries if the WHO was in favour of developed countries. In addition to that, an easy and optimistic start of IMPACT stirred up conflicts of interests in the international community. The problem of poor quality pharmaceuticals became more complicated through the conflicts on intellectual property rights; patented drugs to generic drugs. A key for quality generic products is the formation of a single healthcare service market where good motivation on supply side together with fair competitiveness with patented pharmaceuticals and equitable access to services (both for the rich and the poor) are ensured. Political commitment to investment and regulatory infrastructure for the market is crucial.
650 0 $a Drugs $x Quality control. $3 303164
650 0 $a Pharmaceutical chemistry. $3 203135
650 1 4 $a Public Health. $3 320661
650 2 4 $a Medical Sociology. $3 740035
650 2 4 $a Corporate Social Responsibility. $3 744984
650 2 4 $a Development and Health. $3 785955
700 1 $a Nakamura, Yasuhide. $3 861276
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Trust, interdisciplinary perspectives ; $v 1. $3 776488
856 4 0 $u https://doi.org/10.1007/978-981-15-2089-1
950 $a Social Sciences (Springer-41176)